The American Journal of Managed Care

Overarching Themes in MCL at ASH 2025

Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...
MedPage Today

R2 Maintenance for Elderly MCL Patients Worth the Risk?

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- ...
The American Journal of Managed Care

After CAR T in Mantle Cell Lymphoma, Choices and a Robust Pipeline

Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...
ascopubs.org

Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.

Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study. Innovative approach to determine ...